BioLocal KSA Congress 2026
The BioLocal KSA Congress 2026, held in collaboration with the Society of Hospital Pharmacy, embodies the two inseparable dimensions of pharmaceutical localization…
- 21-22 September ,2026
- Riyadh
- Talents Agency
- Portal Job
Driving pharmaceutical localization.
Connecting Saudi talent with industry leaders.
About Us
Building The Future Of Localization
BioLocal KSA Congress 2026 brings together industry leaders, healthcare institutions, and emerging Saudi talent to accelerate pharmaceutical localization and strengthen national capabilities under Vision 2030.
Supporting Made-in-Saudi pharmaceutical growth while developing the talent that will lead the sector into the future.
Connecting Saudi pharmacy professionals with organizations driving innovation and sector growth.
AGENDA
We Are Always Offering Opportunities For Growth
Explore a forward-looking agenda highlighting the latest innovations in diabetes technology and digital healthcare solutions, led by top regional and international experts.
DAY1 | Monday, 21 September 2026
Session 1
Policy, Regulation & System Readiness
Chair & Moderator
- Dr. Mohammed Alshennawi
Registration & welcome coffee
- 08:00-09:00
Holy Qur'an Recitation & National Anthem
- 09:00-09:30
- Ceremonial & Opening
Opening Keyriote Pharmaceutical Localization: Vision 2030 in Action
- 09:30-10:00
- Eng. Morey Al-Qahtani Deputyship for topokration & Human Capitol Ministry of Health
Opening Keyriote The Local Content Imperative: Raising Saudi Pharmaceutical Content in Government Procurement
- 10:00-10:30
- Local Content & Government Procurement Authonty (LOGPA)
Koynate Made in Saudi: The Industrial Strategy for Pharmaceutical Manufacturing
- 10:30-11:00
- Prof. Mohamed Al Faleh and Eng. Khalid Al Anzi Ministry of Industry & Mineral Resources (MIAR)
Industry Strategic Partner Talk
- 11:00-11:30
- Dr. Faisal Aljuhani
Ponol Discussion From Formulary to Factory: The Vision for Saudi Localization 2030
- 11:30-12:30
- Eng. Marey Al-Qahtani Prof. Mohamed Al Falch Eng. Khalid Al Anzi Local Manufacturer Local Content Leader
Dhuhr Prayer & Lunch
- 12:30-13:30
Session 2
Chair & Moderator
- Dr. Abdulaziz Alhossan
The SFDA Biosimilar Regulatory Pathway: Current State & Future Direction
- 13:30-14:00
- Dr. Ali Al-Somil SFDA
NUPCO's Experience with Biosimilars & Localized Portfolios
- 14:00-14:30
- NUPCO Procurement
Hospital System Readiness: The National Picture
- 14:30-15:00
- Dr Mohammed Alshennawi General Admin of Pharmaceutical Care, Mar
Industry Sponsored Talk
- 15:00-15:30
- TBC
From Policy to Procurement: Aligning Regulators, Payers & Industry
- 15:30-16:30
- ALL
Day 1 closing & preview of Day 2
- 16:30-17:00
DAY 2 | Tuesday, 22 September 2026
Clinical Evidence & Hospital Practice
Session 3
Chair & Moderator:
- Dr. Abdulaziz Alsaqaabi
Registration & coffee
- 08:00-08:45
Day 1 Recap & Day 2 Opening
- 08:45-09:00
- Dr. Mohammed Alshennawi
Biosimilar Evidence & Interchangeability: The Global State of the Science
- 09:00-09:30
- Prof. Hisham Badr Eldin
What a Biosimilar Really Is: The Molecular Science Behind Biologics Manufacturing
- 09:30-09:55
- Dr. Nadin Almosnid Biotechnology Program King Saud bin Abdulaziz University for Health Scienc
Switching Protocols: From Reference Biologic to Biosimilar
- 09:55-10:35
- Dr. Wojdan Aburas General Administration of Pharmaceutical care
- Ministry of Health
Industry Partner Scientific Talk
- 10:35-11:00
Formulary Decisions in Practice: Hospital Case Studies
- 11:00-12:00
- All
From Policy to Practice: Hands-On Implementation Begins
- 12:00-12:30
- Dr. Mohammed Alshennawi
Dhuhr Prayer & Lunch
- 12:30-13:30
DAY 2 | Tuesday, 22 September 2026
WORKSHOP A
Rheumatology
Introductions, workshop scope, faculty panel orientation.
- 13:30-13:40
Anti-TNF biosimilars (adalimumab, etanercept, infliximab) and rituximab in RA. Landmark trials: NOR-SWITCH, DANBIO, BIO-SPAN. The nocebo effect-how real, how to mitigate.
- 13:40-14:15
Case 1: Stable RA patient on reference adalimumab - the switching conversation. Case 2: Managing suspected secondary loss of response after biosimilar switch.
- 14:15-14:50
Design a TNFi biosimilar rollout: patient selection, communication scripts, immunogenicity monitoring, switch-back criteria
- 14:50-15:35
Consensus recommendations across breakout tables.
- 15:35-15:55
Key takeaways and handoff of draft output.
- 15:55-16:00
WORKSHOP OUTPUT:
Rheumatology Biosimilar Switch Protocol + Patient-Conversation Toolkit
DAY 2 | Tuesday, 22 September 2026
WORKSHOP B
GI/IBD
Introductions, workshop scope, faculty panel orientation.
- 13:30-13:40
Infliximab & adalimumab biosimilars in Crohn's disease and ulcerative colitis. Indication extrapolation in IBD - the evidence and the controversy. Therapeutic drug monitoring (TDM) as a safety net.
- 13:40-14:15
Case 1: Infliximab biosimilar switch in stable Crohn's patient. Case 2: UC patient with antibody-mediated loss of response-managing biosimilar-to-biosimilar or biosimilar-to-originator decisions.
- 14:15-14:50
Design a TDM-guided biosimilar protocol for IBD: thresholds, monitoring intervals, escalation pathways.
- 14:50-15:35
Consensus recommendations across breakout tables.
- 15:35-15:55
Key takeaways and handoff of draft output.
- 15:55-16:00
WORKSHOP OUTPUT:
IBD Biosimilar Protocol with embedded TDM algorithm.
DAY 2 | Tuesday, 22 September 2026
WORKSHOP C
Diabetes
Introductions, workshop scope, faculty panel orientation.
- 13:30-13:40
Insulin biosimilars-glargine, lispro. The regulatory nuance (insulins as follow-on biologics, now biosimilars). Device differences: often the real issue, not the molecule. Emerging GLP-1 biosimilars.
- 13:40-14:15
Case 1: T2DM patient converting from originator to biosimilar glargine-hypoglycemia monitoring plan. Case 2: TIDM patient and pen-device change the education protocol. 14:50-15:35 Build an insulin biosimilar conversion protocol:
- 14:15-14:50
Build an insulin biosimilar conversion protocol: patient and device education checklist, hypoglycemia watch period, pharmacist counseling script.
- 14:50-15:35
Consensus recommendations across breakout tables.
- 15:35-15:55
Key takeaways and handoff of draft output.
- 15:55-16:00
WORKSHOP OUTPUT:
Insulin / GLP1 Biosimilar Conversion SOP + Patient Education Leaflet Outline
What We Enable
Advancing Pharmaceutical Localization Through People
Scientific Program
Explore expert-led sessions connecting regulators, manufacturers, and healthcare leaders.
Career Workshop
Gain industry insights and career opportunities for future Saudi pharmacy leaders.
Recruitment Fair
Connect with organizations driving pharmaceutical growth and workforce development.
Industry Collaboration
Build relationships across hospitals, manufacturers, and key industry stakeholders.
Workforce Development
Discover pathways that empower Saudi professionals to lead, operate, and sustain the pharmaceutical sector.
Vision 2030 Impact
Experience how localization drives healthcare and economic outcomes across the Kingdom.
Let’s Build The Future Together
Connect with the BioLocal KSA Congress 2026 team to explore partnerships, participation opportunities, and event inquiries.